论文部分内容阅读
目的探讨长春西汀注射液治疗急性脑梗死的临床疗效及治疗机制。方法将116例急性脑梗死患者分为对照组和治疗组各58例,在常规治疗基础上,治疗组给予长春西汀注射液20mg,同时给予奥扎格雷钠80mg静脉滴注14d;对照组仅给予奥扎格雷钠80mg静脉滴注14d,观察2组治疗前后的临床疗效、神经功能缺损程度评分及血清炎性因子高敏C-反应蛋白(Hs-CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和肿瘤坏死因子α(TNF-α)含量的变化。结果治疗组总有效率89.66%高于对照组的81.3%(P<0.05);治疗组治疗后神经功能缺损程度评分显著降低(P<0.01),血清内Hs-CRP、IL-6、IL-8和TNF-α水平显著降低,差异均有统计学意义(P<0.05)。结论长春西汀注射液通过抗炎性反应机制治疗急性脑梗死。
Objective To investigate the clinical efficacy and mechanism of Vinpocetine Injection in the treatment of acute cerebral infarction. Methods One hundred and sixty-six patients with acute cerebral infarction were divided into control group and treatment group with 58 cases each. On the basis of conventional treatment, the treatment group was given Vinpocetine 20 mg and the intravenous infusion of ozagrel 80 mg for 14 days. The patients were given sodium ozagrel 80 mg intravenously for 14 days. The clinical curative effect, the score of neurological deficit and the levels of serum high sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6) ), Interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) were detected. Results The total effective rate of the treatment group was 89.66%, which was significantly higher than that of the control group (81.3%, P <0.05). The score of neurological deficit in the treatment group was significantly lower (P <0.01), and the levels of Hs-CRP, IL-6 and IL- 8 and TNF-α levels were significantly lower, the differences were statistically significant (P <0.05). Conclusion Vinpocetine can treat acute cerebral infarction through anti-inflammatory response mechanism.